Welcome to BioMarket Group!

Angiogenesis in Oncology Drug Pipeline Update

Additional Information

Published Date Aug 4, 2016
Pages No
License Prices No
PDF Fact Sheet No
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group

Availability: In stock

$2,250.00

Quick Overview

BioSeeker Group have identified 389 companies plus partners who are today developing 428 angiogenesis drugs in 1991 developmental projects in cancer across 288 different targets. In addition, there are 7 suspended drugs and another 218 drugs where development has been ceased.
Request free sample pages from Angiogenesis in Oncology Drug Pipeline Update
Extra value: One year of free online updates included with this product

Executive Summary

BioSeeker Group have identified 389 companies plus partners who are today developing 428 angiogenesis drugs in 1991 developmental projects in cancer across 288 different targets. In addition, there are 7 suspended drugs and another 218 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the Angiogenesis in Oncology Drug Pipeline Update will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work

Our software lets you define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.


The following short video playlist demonstrates the use of the filter sections, how you can make an inclusion and exclusion search and what to expect from a drug profile result.


Some facts about Angiogenesis in Oncology Drug Pipeline Update


There are today 389 companies plus partners developing 428 angiogenesis drugs in 1991 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 218 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 288 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 282 out of the 283 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 61 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Details from Angiogenesis in Oncology Drug Pipeline Update at a glance

This short overview shows actual findings from the Angiogenesis in Oncology Drug Pipeline Update report.

Companies Includes more than 389 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 428 angiogenesis drugs in development, which have a total of 1991 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 37
Registered# 1
Pre-registration# 3
Phase III# 64
Phase II# 172
Phase I# 205
Preclinical# 165
No Data# 25
Suspended# 7
Ceased# 218

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included angiogenesis drugs are also in development for 294 other indications, where of 172 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 282 out of the 283 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 214 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4523 structures available today among drug targets.

Identified drugs are linked to more than 288 different targets, divided into 61 classifications of molecular function:
- Antigen binding
- ATPase activity
- Auxiliary transport protein activity
- Calcium ion binding
- Carboxy-lyase activity
- Carboxypeptidase activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Cofactor binding
- Cysteine-type peptidase activity
- Cytokine activity
-
- Cytoskeletal protein binding
- Deacetylase activity
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Growth factor activity
- GTPase activity
- Heat shock protein activity
- Hormone activity
- Hydrolase activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Lipid kinase activity
- Metallopeptidase activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Peptidase activity
- Peroxidase activity
- Phosphoric diester hydrolase activity
- Protease inhibitor activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- RNA binding
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Sugar-phosphatase activity
- Superoxide dismutase activity
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
- Voltage-gated ion channel activity

Sub-Cellular Localization
Identified targets are categorized into 33 different primary and alternate sub-cellular localizations:
- Cell surface
- Centrosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Extracellular matrix
- Focal adhesion
- Golgi apparatus
- Golgi membrane
- Integral to membrane
- Kinetochore
- Lysosome
- Membrane fraction
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nucleolus
- Nucleoplasm
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisome
- Plasma membrane
- Sarcoplasmic reticulum
- Secreted
- Secretory granule
- Soluble fraction
- Vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 426 protein expression profiles of 268 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 240 Pathways
- KEGG# 188 Pathways
- NCI-Nature# 244 Pathways
- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

Angiogenesis in Oncology Drug Pipeline Update provides you with a profile for each identified drug.
Click here for a short video (6m 12s) showing a typical drug profile

A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Company & Partners Presentation of principal Company and partners.
Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol - Chromosome Location - Gene & Protein Name - Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma - Phase II Clinical Trial - Active
Cancer, prostate - Phase III Clinical Trial - Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions
Analyst comments
Deals and Licensing Collaborations and deals
Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available Preclinical data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data., developmental history and scientific data.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twenty-four different parameters, all of which can be used as inclusion or exclusion parameters, plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report of a selection of drugs that match your criteria.


Application Features Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
Click here for a short video (6m12s) showing a typical drug profile

System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)



License Prices:

Request free sample pages from Angiogenesis in Oncology Drug Pipeline Update

Other selected research from the 'Drugs' category:


IL-5 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More


TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


Hedgehog Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More


IL-2 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 344 companies plus partners who are today developing 449 IL-2 pathway targeting drugs in 1619 developmental projects in cancer across 192 different targets. In addition, there are 6 suspended drugs and another 183 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Proteins in Oncology Drug Pipeline Update
BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More


TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More